Analytics By Light launches µImager to track cell morphology in bioreactors

Analytics By Light said it has incorporated in Delaware and named co-founder Phillip Maderia CEO as it develops the µImager platform for continuous, in-situ cell morphology monitoring in biomanufacturing. The company is lining up early demonstrations with PBS Biotech, Stellix and ARMI to push the technology into cell therapy manufacturing.

Why it matters: - Biomanufacturing process tools can monitor pH, oxygen and temperature, but often miss what cells themselves are doing. - Analytics By Light is aiming to turn cell morphology into a real-time process signal, which could help manufacturers spot drift earlier and reduce the risk of failed lots. - The platform could also reduce sampling and handling, which may lower contamination risk.

What happened: - Analytics By Light announced its incorporation in Delaware as Analytics By Light, Inc. - The company appointed co-founder Phillip Maderia as president and chief executive officer. - Analytics By Light is developing the µImager platform for continuous, in-situ visibility into cell morphology inside bioreactors. - Early demonstration work is underway with PBS Biotech. - Analytics By Light is also working with Stellix on joint customer demonstrations. - The company is engaged with the Advanced Regenerative Manufacturing Institute, or ARMI, to introduce the µImager to ARMI’s regenerative medicine member network.

The details: - The µImager is described as a first-in-class, bioreactor-agnostic, through-wall imaging system. - The platform measures cell and aggregate morphology without episodic sampling. - The system converts cell diameter, aggregate size and shape factors into machine-readable process data. - Analytics By Light says the resulting signal changes can reveal shifts in cell state during a batch. - The company says that earlier visibility can create an opportunity to correct a process while the batch can still be steered. - Maderia brings more than 35 years of biopharmaceutical manufacturing leadership. - Co-founder Dave Kane serves as vice president of engineering and operations. - Co-founder J.P. Jiang invented the µImager’s core imaging approach and quantitative morphology methods. - Kane has four decades of experience building electro-optical and medical-device hardware. - Bloom Bio is supporting Analytics By Light with life-sciences commercialization and growth advisory work. - Bloom Bio founder Kimberly Negrin said continuous, in-situ morphology measurement could transform morphology from an observation into a process signal. - Negrin said reduced reliance on sampling and handling could also reduce contamination risk and improve process decision-making. - Analytics By Light says the µImager platform’s initial applications are in cell therapy. - The company also says the platform has a path toward closed-loop and autonomous biomanufacturing. - More information is available at analyticsbylight.com.

Between the lines: - The announcement targets a persistent gap in bioprocess analytics: researchers can measure the environment around cells, but not always the cells' physical state in real time. - If the platform works as intended, morphology could become another controllable manufacturing variable instead of a post-sampling observation. - The partner list suggests Analytics By Light is trying to validate the system with both technology providers and regenerative medicine operators before broad commercialization.

What's next: - The company will continue early demonstration work with PBS Biotech. - Joint customer demonstrations with Stellix are expected to continue. - Analytics By Light will use its ARMI connection to reach additional regenerative medicine organizations. - The company’s broader push appears aimed at moving the µImager from demonstration into cell-therapy manufacturing workflows.

The bottom line: - Analytics By Light is betting that real-time morphology sensing can fill a major blind spot in biomanufacturing and help manufacturers act before a batch goes off track.